V843I, a Lung Cancer Predisposing EGFR Mutation, Is Responsible for Resistance to EGFR Tyrosine Kinase Inhibitors
- 1 September 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 9 (9), 1377-1384
- https://doi.org/10.1097/jto.0000000000000241
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitorsCancer Treatment Reviews, 2011
- Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary ReportClinical Cancer Research, 2010
- Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasJCI Insight, 2007
- ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancerBritish Journal of Cancer, 2007
- Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance MutationCancer Research, 2007
- EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase ActivityCancer Research, 2007
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Validation of the general purpose QUANTA ®3.2/CHARMm® force fieldJournal of Computational Chemistry, 1992